Disease

health

Cites Link to Nonalcoholic Fatty Liver Disease and Importance of Early Detection

Echosens, a high-technology company offering the FibroScan family of products, urges increased awareness of the rise of liver cancer rates, which have more than tripled since 1980, while death rates have more than doubled during this time. About 21,000 Americans are diagnosed with primary liver cancer each year—twice as common in men than in women. Risk factors include other liver diseases, including cirrhosis, chronic hepatitis B, chronic hepatitis C and non-alcoholic fatty liver disease (NAFLD). NAFLD may be a key driver of increased cancer associated with obesity, while non-alcoholic steatohepatitis (NASH) is the fastest growing cause of liver cancer among transplant candidates.

“People with NAFLD have higher rates of several types of cancer, with the greatest increase seen for liver cancer and other gastrointestinal cancers,” says Jon Gingrich, CEO, Echosens North America. “Point-of-care examinations, monitoring and ongoing assessment of liver fat and stiffness as provided by FibroScan, a rapid, non-invasive point of care examination, can identify individuals who are asymptomatic and undiagnosed for liver damage.”

Researchers have found that liver cancer, NAFLD, hepatitis C and liver transplants are prevalent in 40-80% of people who have Type 2 diabetes and in 30-90% of people who are obese. Being overweight or obese is responsible for about 85% of fatty liver disease.

“Approximately 30,000 people die from liver cancer each year and these numbers have continued to rise in recent years,” says Lynn Gardner Seim, Executive Vice President and Chief Operating Officer, American Liver Foundation. “It is essential that patients at risk for liver cancer, including those who have previously been diagnosed with hepatitis C, NAFLD, NASH and other liver diseases, talk with their doctors and have a plan in place for getting screened.”

Traditional approaches to assessing liver health, such as liver biopsy and advanced radiological imaging, may not be cost effective nor accessible to the broader at-risk population. FibroScan directly measures physical properties of stiffness and fat liver to provide reproducible results and allow for both diagnosis and monitoring of liver stiffness and liver fat. It is also recognized worldwide as the reference for non-invasive liver diagnosis supported with more than 2,000 medical publications and 40 guideline recommendations.

About Echosens

Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans. For more information, please visit http://www.echosens.us and follow us on Twitter (@echosensNA).

View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005599/en/

Contacts

Media:
Brittany Tedesco
CPR Communications
btedesco@cpronline.com
201.641.1911 x 14

Source Article

Read More
health

Bilingualism Benefits The Brain, Helps Delay Onset Of Alzheimer’s Disease

KEY POINTS

  • Bilingualism prompts the brain to work harder
  • It helps in keeping the brain healthy
  • Learning a new language is possible even in adulthood

The Alzheimer’s Association revealed that more than five million Americans are currently living with the disease and the number is projected to reach 14 million by 2050. The numbers may be grim, but recent research showed that there is one way to delay its onset, and that is through bilingualism. Learning a new language at any age can greatly help keep the brain healthier.

Dr. Ellen Bialystok, a Canadian psychologist and professor who has the rank of Distinguished Research Professor at York University, Toronto, has made one of the most compelling researches on the relationship between bilingualism and the brain. Bialystok, in a research published in Neurology, titled, “Delaying the onset of Alzheimer’s disease, Bilingualism as a form of cognitive reserve,” revealed that bilinguals often receive a diagnosis of Alzheimer’s about four to five years later than monolinguals. 

“The more you use another language, the better you get at it. Well, that’s not surprising, but along with that, the more you use two languages, the more your brain subtly rewires,” Bialystok told CNN 

Bialystok noted that in terms of the benefits that the brain gets when it comes to bilingualism, levels of education do not matter at all. She highlighted that one of the most profound results of bilingualism was observed among illiterates or those who did not have any formal education. Speaking two languages was the only real way that their brains receive stimulation, such that the exercise provides protection to their brains as they grow older.

Bilingualism good for the brain Bilingualism benefits the brain. Photo: jamesoladujoye/Pixabay

Bialystok stated that the number of years that one speaks two languages would mean a longer period that the brain keeps on reorganizing. The earlier that people start becoming bilingual, the better.

Tamar Gollan, professor at the University of California, San Diego, said that people could not just turn off a language. Bilinguals are faced with everyday choices that monolinguals do not face. To this effect, the brain works harder to speak two languages.

Learning a new language even as an adult can greatly benefit brain health. Just like exercise, wherein the more that one exercise, the greater that one expands his capacity for oxygen. By exercising the brain more through bilingualism, the brain maintains its flexibility. Add in physical activities, eating healthy and sufficient amounts of sleep, and one may be able to keep the brain healthier.

Source Article

Read More
health

An Unexpected Finding on What Might Drive Joint Disease | Health News

By Steven Reinberg, HealthDay Reporter

(HealthDay)

FRIDAY, Oct. 23, 2020 (HealthDay News) — High levels of a protein that lubricates the knee joint may actually be a harbinger of impending joint disease, a surprising animal study suggests.

The researchers looked at the role of the protein, known as lubricin, in anterior cruciate ligament (ACL) injuries in dogs because it may also be involved in similar injuries in humans.

“Lubricin is crucial for normal joint function and the lubrication of cartilage,” said researcher Heidi Reesink, an assistant professor in equine health at the College of Veterinary Medicine at Cornell University. “We know that if a person or animal doesn’t make that protein, they will develop devastating joint disease affecting all the major weight-bearing joints.”

But Reesink found that in dogs that suffered a ligament tear in the knee, lubricin levels increased within the joint, which is the opposite of the conventional assumptions. “The dogma in this field has been that lubricin decreases in joint disease,” Reesink said in a university news release.

The researchers found that in three dogs, lubricin increased in the time between the initial injury but before any signs of arthritis.

“This indicates that the presence of increased lubricin might actually be a biomarker for predicting future osteoarthritis,” Reesink said. “We also saw increased lubricin in dogs months to years after they injured their ACLs, suggesting that lubricin might be an indicator of ongoing joint instability.

“In looking at horses and dogs, we’re seeing the same pattern,” Reesink said. “The strongest piece of data would be to show it in humans as well.” However, findings in animal studies don’t always translate to humans.

Increased lubricin could become a signal for doctors to intervene or try a different treatment, she added.

The study was published recently in the journal Scientific Reports.

Copyright © 2020 HealthDay. All rights reserved.

Source Article

Read More
health

Excess lipids in nerve cells may trigger Parkinson’s disease

Researchers have discovered an imbalance in the amounts of fatty molecules called lipids inside the brain cells of people with Parkinson’s disease. A buildup of lipids in nerve cells may cause inflammation.

Parkinson’s disease is a movement disorder that gets progressively worse over time.

The death of dopamine-producing nerve cells in the substantia nigra region of the brain causes the illness. Dopamine is a neurotransmitter that plays several vital roles, including regulating motivation, reward, and movement.

However, the exact train of events leading to the death of dopamine-producing cells remains unclear.

Researchers have focused much of their attention on a misfolded form of a protein called alpha-synuclein as the trigger for Parkinson’s. Studies have found toxic clumps or aggregates of the misfolded protein in the brains of people with the disease.

However, an alternative theory proposes that lipid dysregulation and inflammation play a more important role, similar to the part played by fatty plaques and inflammation in the walls of arteries in cardiovascular disease.

Researchers at the Neuroregeneration Institute at McLean Hospital in Belmont, MA, have now discovered an accumulation of lipids in dopamine-producing neurons in the postmortem brains of people who had Parkinson’s.

The excess amounts of lipid in these nerve cells correlate with changes in lipid levels in neighboring cells called microglia and astrocytes. They also found evidence of inflammation.

When the researchers simulated a breakdown of lipid metabolism in an animal model of the disease, they saw remarkably similar changes.

“These results support our lipid-inflammation hypothesis in the causation of Parkinson’s disease initiation and progression,” says senior author Dr. Ole Isacson, who is the founding director of the Neuroregeneration Institute and a professor of neurology at Harvard Medical School in Boston, MA.

“[The results] may help us discover and develop new therapies by leaving behind conventional thinking about [Parkinson’s disease] pathology, which to some extent has been limited to neurons and protein aggregates,” he adds.

The study appears in the journal Proceedings of the National Academy of Sciences.

The scientists compared postmortem brain tissue from 26 individuals with Parkinson’s with 23 age-matched controls without the disease.

They used fluorescent lipid-binding molecules to determine lipid levels in different brain cells in the substantia nigra.

In brain tissue from people with Parkinson’s, there was an accumulation of lipids inside dopamine nerve cells, which was matched by a deficiency of lipids within astrocytes in the same samples.

Astrocytes are star-shaped cells that support nerve cells, both structurally and through the exchange of nutrients and their byproducts.

In their paper, the researchers note that nerve cells have a limited capacity to use lipids for energy, with excess amounts being transported to neighboring astrocytes to avoid the buildup of toxic byproducts.

This did not seem to be happening correctly in the brains of individuals with Parkinson’s.

Compared with healthy brain tissue, the scientists also found excess amounts of lipid inside microglia, which are the brain’s immune cells.

They also discovered high levels of a signaling molecule called GPNMB. Scientists know that

Read More
health

Childhood Absence Epilepsy Treatment Market Research Report by Drug, by Disease Type – Global Forecast to 2025

Childhood Absence Epilepsy Treatment Market Research Report by Drug (Lamotrigine, Phase 2 Drugs, and Valproate), by Disease Type (Atypical Absence Seizures and Typical Absence Seizures) – Global Forecast to 2025 – Cumulative Impact of COVID-19

New York, Oct. 22, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Childhood Absence Epilepsy Treatment Market Research Report by Drug, by Disease Type – Global Forecast to 2025 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p05913817/?utm_source=GNW

The Global Childhood Absence Epilepsy Treatment Market is expected to grow from USD 181.92 Million in 2019 to USD 263.89 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.39%.

Market Segmentation & Coverage:
This research report categorizes the Childhood Absence Epilepsy Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug, the Childhood Absence Epilepsy Treatment Market studied across Lamotrigine, Phase 2 Drugs, and Valproate.

Based on Disease Type, the Childhood Absence Epilepsy Treatment Market studied across Atypical Absence Seizures and Typical Absence Seizures.

Based on Geography, the Childhood Absence Epilepsy Treatment Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Childhood Absence Epilepsy Treatment Market including AbbVie, Cavion, Inc., GlaxoSmithKline plc, Insys Therapeutics, Pfizer Inc., Pfizer Inc., and Teva Pharmaceutical Industries Ltd..

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Childhood Absence Epilepsy Treatment Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain,

Read More
medicine

Keck Medicine of USC enrolling individuals in phase 3 clinical trial to treat mild Alzheimer’s disease using deep brain stimulation

IMAGE

IMAGE: Darrin Lee, MD, PhD, a neurosurgeon with Keck Medicine of USC and the principal investigator of the site’s clinical trial
view more 

Credit: Image courtesy of Ricardo Carrasco III of Keck Medicine of USC

LOS ANGELES — An estimated 5.5 million people in the United States live with Alzheimer’s disease, which is the most common form of dementia.

Keck Medicine of USC is enrolling individuals in an international phase 3 clinical trial to examine the safety and effectiveness of deep brain stimulation to treat Alzheimer’s. The study uses electrical impulses to stimulate the region of the brain known as the fornix, which is associated with memory and learning.

“Deep brain stimulation has successfully treated conditions such as Parkinson’s disease by improving motor skills, and we are now investigating if this therapy can stabilize or improve cognitive function,” says Darrin Lee, MD, PhD, a neurosurgeon with Keck Medicine of USC and the site’s principal investigator of the study. “Based on the results of earlier phases of this clinical trial, the treatment offers a potential benefit for patients with mild Alzheimer’s.”

This randomized, double-blind study will last four years. Subjects will first take a standardized assessment test for Alzheimer’s to be used as a baseline measure of cognitive ability throughout the study.

Next, researchers will implant electrodes into subjects’ brains that connect to a battery pack, similar to a heart pacemaker, placed underneath the collarbone.

For the first year of the study, subjects will be given either low-frequency stimulation to the brain, high-frequency stimulation or a placebo — no stimulation.

“For those with Alzheimer’s disease, certain parts of the brain become atrophied,” Lee says. “We are testing to see if stimulating the brain’s fornix can reawaken brain activity in this area and stop the progression of the disease.”

During the first year, subjects will be given subsequent cognitive tests to check if their memory or learning skills have held steady or improved. At the end of the year, study researchers will examine data to determine which level of stimulation had the most impact on these skills.

For the next three years of the trial, all subjects in the study will receive what researchers have determined is the optimal frequency of deep brain stimulation, even those originally receiving the placebo. Patients will continue to be given cognitive assessments throughout the four-year period.

To qualify for the trial, patients must be 65 or older, have been diagnosed with mild Alzheimer’s and take Alzheimer’s medication, and have a caregiver or family member who can accompany them to doctor visits.

The clinical trial involves approximately 200 patients at some 20 sites in the United States, Canada and Germany. Keck Medicine plans to enroll 8-15 patients.

The trial is sponsored by Functional Neuromodulation, Inc.

Those interested in enrolling in the clinical trial with Keck Medicine can contact Amanda Romano at amanda.romano@med.usc.edu or 213-393-5640.

###

Keck Medicine co-investigators of the trial include psychiatrist Carlos Manuel Figueroa, MD, and neurologist Elizabeth Joe, MD.

Deep brain stimulation has been

Read More
health

The global kidney disease market is expected to reach US$ 133,444.71 million by 2027 from US$ 81,128.11 million in 2019

The market is estimated to grow at a CAGR of 6. 5% from 2020 to 2027. High prevalence of chronic diseases leading to kidney diseases, and favorable reimbursement policy for the kidney disease treatments are the major factorsdriving the growth of the kidney disease market.

New York, Oct. 20, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Kidney Disease Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Product Type ; End User, and Geography” – https://www.reportlinker.com/p05978086/?utm_source=GNW
However, the undiagnosed cases of kidney diseaseare hindering the growth of the market.
Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people worldwide.High blood pressure and diabetes were the two major causes in 75% of kidney failure cases between 2015 and 2017.

Moreover, according to a study published by the National Kidney Foundation in 2020, around 35.0% of the diabetic population above age 20 years would develop chronic kidney disease over the period of time.
As per the data published by the National Kidney Foundation Inc., in 2020, CKD is likely to cause more deaths than prostate cancer or breast cancer. It is an under-recognized emergency health condition among people. 1 in 3 American adults (about 80 million people) is at a risk due to CKD.

According to the estimates given by the Centers of Disease Control and Prevention (CDC) in 2020, 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might have chronic kidney disease. In 2015, 30.3 million people in the US had diabetes as per the American Diabetes Association. According to the CDC, in 2014, around 118,000 people in the US started the treatment for end-stage renal disease, and the number of people taking this treatment is expected to increase as more people become aware of this condition. Moreover, the CDC states that around 96% of the people with kidney damage are not aware of having chronic kidney disease, which indicates the underlying market prospective in the kidney disease market. These factors are expected to enhance the market growth during the forecast period.
The global kidney disease market is segmented based onproduct type and end user.Based on product type, the market is segmented into diagnosis and treatment.

The diagnosis segment held the largest share of the market in 2019 and the same segment is anticipated to register the highest CAGR in the market during the forecast period.In terms of enduser, the kidney disease market has been segmented into hospitals, diagnostic laboratories, and others.
Saudi Center for Organ Transplantation,South Australian Health and Medical Research Institute,World Health Organization, Pharmaceuticals and Medical Devices Agency, European Medical Association, World Trade Organization, Pharmaceutical Research and Manufacturers of America, and European Federation of Pharmaceuticals Industries Associations are among the essential secondary sources referred to while preparing this report.
Read the full report: https://www.reportlinker.com/p05978086/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you

Read More
health

Coronavirus Testing Delays Still Prevent Effective Disease Control, Survey Finds : Shots

People wait in the shade while in line to get Covid-19 tests in Revere, MA.

David L. Ryan/Boston Globe via Getty Images


hide caption

toggle caption

David L. Ryan/Boston Globe via Getty Images

People wait in the shade while in line to get Covid-19 tests in Revere, MA.

David L. Ryan/Boston Globe via Getty Images

People are getting the results of coronavirus tests in the U.S. faster than they were in the spring, but testing still takes far too long to help effective disease control measures such as contact tracing and quarantining, according to the results of a large national survey.

The survey, which is conducted monthly by a consortium of researchers from Northeastern, Northwestern, Harvard and Rutgers universities, also finds that Hispanics and African-Americans are waiting about a day longer than whites on average, underscoring yet another way the pandemic is hitting minorities harder.

The researchers also found that a disturbingly high proportion of those testing positive — almost half — are never contacted by a health worker to determine who they may have infected, a crucial step for preventing outbreaks.

“That is how you limit the spread of the disease and limit the number of people who have to socially isolate and avoid lockdowns,” says Dr. David Lazer of Northeastern University, who led the team conducting the survey. “The good news is there has been some improvement. The bad news is everything is still taking far too long.”

The researchers surveyed 52,329 people in all 50 states and the District of Columbia in July, August and September as part of a series of ongoing surveys the team has been conducting since April.

Of those surveyed, 12,911 got a coronavirus test, including 8,843 whose sample was collected with a nasal swab.

Among that group, the average wait time for results was 2.7 days in September, down from four days in April, the researchers found. In addition, the proportion of people getting their results back within 24 hours increased from 23% to 37%.

While that’s an improvement, the turnaround time is still “too slow in most cases to support a successful strategy of contact tracing,” and most people are still waiting far too long, the researchers wrote.

“Despite decreased average wait times, a substantial proportion of Americans still endure long waits,” they added.

They noted that in September, 42% of those tested had to wait at least three days before getting their results.

The average black respondent waited 4.4 days to receive results and the average Hispanic respondent waited 4.1 days. In comparison, white and Asian American respondents respectively waited an average of 3.5 and 3.6 days, the researchers found.

“We know that African-Americans and Hispanics are underserved medically,” Lazer says. “This is reflective of that larger reality. It’s terrible.”

To keep outbreaks from occurring, people who are infected need to be contacted quickly, ideally within 24-36 hours to make sure they don’t infect other people and find out who they may have come into contact with so those people

Read More
fitness

Ukrainian fitness influencer Dmitriy Stuzhuk, who once thought there was no COVID-19, succumbs to disease



a person wearing a mask: Ukrainian fitness influencer Dmitriy Stuzhuk, who once thought there was no COVID-19, succumbs to disease


© Saurav Mukherjee
Ukrainian fitness influencer Dmitriy Stuzhuk, who once thought there was no COVID-19, succumbs to disease

Famous Ukrainian fitness influencer and social media star Dmitriy Stuzhuk, who once thought that there was no COVID-19, died from the virus at the age of 33.

The Ukrainian citizen believed that the coronavirus does not exist. He caught the disease during a trip to Turkey. He was taken to hospital when he landed in Ukraine after being tested COVID-19 positive, reports the Sky News.

Though Stuzhuk was discharged from the hospital after eight days, he faced heart complications due to the COVID-19 virus. Following this, his 25-year-old wife Sofia rushed him to the hospital in a “grave condition” and “unconscious” state.

Hope Hicks shares stage with Donald Trump in Florida after testing COVID positive.

Informing about the developments, she told her Instagram followers that her husband is not coping as he had problems with his cardiovascular system. “His state is extremely grave. No-one can do anything with this. I did everything I could so the father of my three children lives. But nothing depends on me now,” Sky News quotes wrote Sofia as saying.

However, she later announced her husband’s death, and wrote, “Only warm memories remain, three beautiful kids and valuable experience.”

Prior to being admitted for the second time, Stuzhuk had posted on social media from his hospital bed.

He had written to his 1.1 million followers, “I want to share how I got sick and to strongly warn everyone. I was one who thought that Covid does not exist…until I got sick.”

“COVID-19 IS NOT A SHORT-LIVED DISEASE! And it is heavy,” he had said. Stuzhuk and Sofia had separated six months ago.

View this post on Instagram

КОРОНАВИРУС «COVID», ДЕНЬ 8 ⠀ Как вы все знаете из историй, я болею корлнавирусом. Сегодня, вернувшись домой, первый раз появился энтузиазм хотя бы что-то написать. Хочу поделиться, как я заболел и убедительно предостеречь всех: я тоже думал, что нет никакого ковида, и это все относительно. Пока сам не заболел. COVID-19 БОЛЕЗНЬ НЕ ЭФЕМЕРНАЯ! И тяжелая. Но обо всем по порядку. ⠀ Как это было? Плохо мне стало на второй день в Турции. Я проснулся среди ночи от того, что у меня отекла шея и было тяжело дышать. При этом немного побаливал живот. ⠀ На следующий день начал появляться кашель, но температуры никакой не было. Особых симптомов болезни тоже не было, поэтому я подумал, что это могут быть последствия после занятия спортом, смены климата и питания ну и плюс сон под кондиционером. ⠀ После возвращения из Турции я сразу же пошел сдавать разные анализы, делать УЗИ и на всякий случай решил пройти тест на COVID. Он оказался положительным

Source Article

Read More
health

Infectious Disease Expert Contradicts Anthony Fauci, Reveals How Thanksgiving Travel Could Be Safe

While Dr. Anthony Fauci is warning against large family gatherings and travel for the upcoming Thanksgiving holiday in the U.S., another health expert is saying that those who utilize proper precautions should be okay to do some traveling over the holidays.

Speaking to WPTV, an NBC affiliate station, Dr. Kleper De Almeida, an infectious disease specialist with JFK Medical Center in Atlantis, Florida, said that he felt travel could take place over the holiday season, including Thanksgiving, so long as those choosing to travel did so in a smart and safe way.

“As long as people take the measures that we should be applying every day, it would be safe to travel,” he said. “We need to be very mindful of that while we travel to protect ourselves from exposure, and in doing so, minimizing the risk of bringing it back to our communities.”

De Almeida’s comments directly contradict ones made by Fauci, who is the head of the National Institute of Allergy and Infectious Diseases and has been seen as the face of COVID-19, as he repeatedly warns Americans of rising infection rates and encourages mask use and social distancing. However, while those measures can help slow the spread, he has warned against letting them be the sole means of protection when it comes to considering a larger gathering for Thanksgiving and even admitted that he was taking precautions by not spending the holiday with his own daughters.

“That is unfortunately a risk, when you have people coming from out of town, gathering together in an indoor setting,” Fauci said. It is unfortunate, because that’s such a sacred part of American tradition—the family gathering around Thanksgiving. But that is a risk.”

The CDC echoed Fauci’s concerns with their guidelines for the holiday season, and traditional events that draw large crowds, like the Macy’s Thanksgiving Day Parade in New York, are going virtual to try and prevent the spread.

The United States currently stands at more than 8 million total COVID-19 infections reported and 218,000 deaths, with more than 70,000 new cases reported Friday, the largest increase since July. According to statistics from the New York Times, a total of 29 states continue to report high numbers of cases, while 16 other states are starting to report upticks.

In the past seven days, states that have seen high surges in percentages of cases have been North and South Dakota, which have seen more than 500 cases per 100,000 residents, with Montana, Wisconsin and Nebraska also reporting high numbers, with more than 300 cases per 100,000 residents. Currently, the only states that have seen less than 100 infections per 100,000 people (less than 0.001 percent), have been Vermont, Maine, Hawaii, New Hampshire, New York, Oregon, California, Washington, New Jersey, Massachusetts, Maryland, Arizona, Pennsylvania, Connecticut, Virginia, Florida, Delaware, Georgia and Louisiana.

Fauci said the government would not make any future COVID-19 vaccine obligatory for the general public Fauci said the government would not make any future COVID-19 vaccine obligatory for the general public Photo: POOL / Al Drago

Source Article

Read More